search
Back to results

COGNITIVE BEHAVIORAL THERAPY PROGRAM TO FIRST-EPISODE PSYCHOSIS PATIENTS AND CANNABIS ABUSE

Primary Purpose

First-episode Psychosis, Cannabis Abuse

Status
Completed
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Cognitive-behavioral therapy program to first-episode psychosis patients and cannabis abuse
Psychoeducation
Sponsored by
Basque Health Service
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for First-episode Psychosis

Eligibility Criteria

15 Years - 40 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. - Having a first psychotic episode. DSM-IV-TR diagnosis of a psychotic disorder (i.e. schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, bipolar disorder, atypical psychosis, brief psychotic disorder, or major depressive disorder with psychotic symptoms).
  2. - Being a regular cannabis user according DSM-IV
  3. -Being in remission from the first psychotic episode (not exceeding 5 years).

Exclusion Criteria:

  1. Presenting organic brain pathology.
  2. Presenting mental retardation according to DSM-IV criteria.

Sites / Locations

  • Araba University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Experimental group

Control group

Arm Description

The subjects of experimental group will receive a cognitive-behavioral treatment program specific for reduce cannabis use composed of 16 weekly sessions (one hour in duration), in addition to regular psychiatric review and pharmacological treatment. The group will consist of 6-8 subjects.

The control group will receive standard care for psychotic episodes which includes pharmacological treatment and psychoeducation, following the same format as the experimental group. 16 weekly sessions of psychoeducation (one hour in duration) will be conducted, in addition to regular psychiatric review and pharmacological treatment. Like the experimental group the group will consist of 6-8 subjects.

Outcomes

Primary Outcome Measures

Cannabis use reduction in the follow-up
To assess whether cannabis focused psychological intervention is associated with a cannabis use reduction according to Europ-ASI scale compared to standard treatment
Improvement in the development of psychotic disorder
To assess whether cannabis focused psychological intervention is associated with an improvement in the development of psychotic disorder (ie, reduction of symptoms and improvement of psychosocial functioning) compared with standard treatment at the end of treatment and at follow-up (at three and six months and one year of follow-up).
Changes in the components of the endogenous cannabinoid system
To determine whether changes in the components of the endogenous cannabinoid system at systematic level are produced in FEP cannabis abusers.
Normalizing the possible alterations in the endogenous cannabinoid system
To assess whether treatment program specific for cannabis abstinence is capable of normalizing the possible alterations in the endogenous cannabinoid system in patients that reduce the cannabis use.

Secondary Outcome Measures

Decrease the number of cannabis users
To determinate the number of patient who use cannabis in the follow-up in each group
Decrease of negative and positive psychotic symptoms
To compare the decrease of negative and positive psychotic symptoms measured by Positive and Negative Syndrome Scale (PANSS), at post-treatment and follow-up.
Decrease of manic, depressive and anxiety symptoms
To compare the decrease of manic, depressive and anxiety symptoms at post-treatment and follow-up. Manic symptoms will be measured using Young Mania Rating Scale (YMRS). Anxiety and depressive symptoms will be measured using Hamilton Anxiety Scale (HAM-A) and Hamilton Depression Scale (HAM-D), respectively.
Improvement in the psychosocial functioning
To compare the improvement of psychosocial functioning in each group by Functioning Assessment Short Test (FAST).
Improvement in the adherence to pharmacological treatment
To compare the adherence to pharmacological treatment in each group using Morisky-Green Scale.
Withdrawal of patients
To evaluate percentage of withdrawal in the follow-up.
Decrease the number of relapses and rehospitalizations
To compare the number of relapses and rehospitalizations in in each group.

Full Information

First Posted
December 10, 2014
Last Updated
January 15, 2020
Sponsor
Basque Health Service
search

1. Study Identification

Unique Protocol Identification Number
NCT02319746
Brief Title
COGNITIVE BEHAVIORAL THERAPY PROGRAM TO FIRST-EPISODE PSYCHOSIS PATIENTS AND CANNABIS ABUSE
Official Title
COGNITIVE BEHAVIORAL THERAPY PROGRAM TO FIRST-EPISODE PSYCHOSIS PATIENTS AND CANNABIS ABUSE
Study Type
Interventional

2. Study Status

Record Verification Date
January 2020
Overall Recruitment Status
Completed
Study Start Date
September 2013 (Actual)
Primary Completion Date
September 2018 (Actual)
Study Completion Date
September 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Basque Health Service

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
General objective: To assess the effectiveness of a treatment program specific for cannabis abuse (cognitive behavioral treatment + pharmacological treatment) compared to standard treatment (pharmacological treatment + psychoeducation) in patients with first episodes psychosis (FEP) cannabis users. Design A multicenter single-blind randomized study with 1 year of follow-up. The effectiveness of a treatment program specific for cannabis abuse (cognitive behavioral treatment + pharmacological treatment) compared to standard treatment (pharmacological treatment + psychoeducation) in patients with first episodes psychosis (FEP) cannabis users will be assessed. Patients will be randomly assigned to one of two treatments: Experimental group (N=50): Cognitive-behavioral treatment specific for cannabis abuse + pharmacological treatment Control group (N=50): standard treatment: psychoeducation + pharmacological treatment

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
First-episode Psychosis, Cannabis Abuse

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
88 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Experimental group
Arm Type
Experimental
Arm Description
The subjects of experimental group will receive a cognitive-behavioral treatment program specific for reduce cannabis use composed of 16 weekly sessions (one hour in duration), in addition to regular psychiatric review and pharmacological treatment. The group will consist of 6-8 subjects.
Arm Title
Control group
Arm Type
Active Comparator
Arm Description
The control group will receive standard care for psychotic episodes which includes pharmacological treatment and psychoeducation, following the same format as the experimental group. 16 weekly sessions of psychoeducation (one hour in duration) will be conducted, in addition to regular psychiatric review and pharmacological treatment. Like the experimental group the group will consist of 6-8 subjects.
Intervention Type
Behavioral
Intervention Name(s)
Cognitive-behavioral therapy program to first-episode psychosis patients and cannabis abuse
Intervention Description
The intervention program is focused on reducing the cannabis use, improving awareness of illness, adherence to treatment, identification of prodromes, psychosocial functioning improvement and relapse prevention.
Intervention Type
Behavioral
Intervention Name(s)
Psychoeducation
Intervention Description
The aim of psychoeducation is that the patient understands and be able to manage the disease providing the tools and skills to symptoms management, to avoid relapse and contribute to their wellbeing.
Primary Outcome Measure Information:
Title
Cannabis use reduction in the follow-up
Description
To assess whether cannabis focused psychological intervention is associated with a cannabis use reduction according to Europ-ASI scale compared to standard treatment
Time Frame
Baseline, 16 weeks (posttreatment), at 3 and 6 months and at one year of follow up.
Title
Improvement in the development of psychotic disorder
Description
To assess whether cannabis focused psychological intervention is associated with an improvement in the development of psychotic disorder (ie, reduction of symptoms and improvement of psychosocial functioning) compared with standard treatment at the end of treatment and at follow-up (at three and six months and one year of follow-up).
Time Frame
Baseline, 16 weeks (posttreatment), at 3 and 6 months and at one year of follow up
Title
Changes in the components of the endogenous cannabinoid system
Description
To determine whether changes in the components of the endogenous cannabinoid system at systematic level are produced in FEP cannabis abusers.
Time Frame
Baseline, 16 weeks (posttreatment), at 3 and 6 months and at one year of follow up
Title
Normalizing the possible alterations in the endogenous cannabinoid system
Description
To assess whether treatment program specific for cannabis abstinence is capable of normalizing the possible alterations in the endogenous cannabinoid system in patients that reduce the cannabis use.
Time Frame
Baseline, 16 weeks (posttreatment), at 3 and 6 months and at one year of follow up
Secondary Outcome Measure Information:
Title
Decrease the number of cannabis users
Description
To determinate the number of patient who use cannabis in the follow-up in each group
Time Frame
Baseline, 16 weeks (posttreatment), at 3 and 6 months and at one year of follow up
Title
Decrease of negative and positive psychotic symptoms
Description
To compare the decrease of negative and positive psychotic symptoms measured by Positive and Negative Syndrome Scale (PANSS), at post-treatment and follow-up.
Time Frame
Baseline, 16 weeks (posttreatment), at 3 and 6 months and at one year of follow up
Title
Decrease of manic, depressive and anxiety symptoms
Description
To compare the decrease of manic, depressive and anxiety symptoms at post-treatment and follow-up. Manic symptoms will be measured using Young Mania Rating Scale (YMRS). Anxiety and depressive symptoms will be measured using Hamilton Anxiety Scale (HAM-A) and Hamilton Depression Scale (HAM-D), respectively.
Time Frame
Baseline, 16 weeks (posttreatment), at 3 and 6 months and at one year of follow up
Title
Improvement in the psychosocial functioning
Description
To compare the improvement of psychosocial functioning in each group by Functioning Assessment Short Test (FAST).
Time Frame
Baseline, 16 weeks (posttreatment), at 3 and 6 months and at one year of follow up
Title
Improvement in the adherence to pharmacological treatment
Description
To compare the adherence to pharmacological treatment in each group using Morisky-Green Scale.
Time Frame
Baseline, 16 weeks (posttreatment), at 3 and 6 months and at one year of follow up
Title
Withdrawal of patients
Description
To evaluate percentage of withdrawal in the follow-up.
Time Frame
Baseline, 16 weeks (posttreatment), at 3 and 6 months and at one year of follow up
Title
Decrease the number of relapses and rehospitalizations
Description
To compare the number of relapses and rehospitalizations in in each group.
Time Frame
Baseline, 16 weeks (posttreatment), at 3 and 6 months and at one year of follow up

10. Eligibility

Sex
All
Minimum Age & Unit of Time
15 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: - Having a first psychotic episode. DSM-IV-TR diagnosis of a psychotic disorder (i.e. schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, bipolar disorder, atypical psychosis, brief psychotic disorder, or major depressive disorder with psychotic symptoms). - Being a regular cannabis user according DSM-IV -Being in remission from the first psychotic episode (not exceeding 5 years). Exclusion Criteria: Presenting organic brain pathology. Presenting mental retardation according to DSM-IV criteria.
Facility Information:
Facility Name
Araba University Hospital
City
Vitoria
State/Province
Alava
ZIP/Postal Code
01002
Country
Spain

12. IPD Sharing Statement

Citations:
PubMed Identifier
27473688
Citation
Gonzalez-Ortega I, Echeburua E, Garcia-Alocen A, Vega P, Gonzalez-Pinto A. Cognitive behavioral therapy program for cannabis use cessation in first-episode psychosis patients: study protocol for a randomized controlled trial. Trials. 2016 Jul 29;17:372. doi: 10.1186/s13063-016-1507-x.
Results Reference
derived

Learn more about this trial

COGNITIVE BEHAVIORAL THERAPY PROGRAM TO FIRST-EPISODE PSYCHOSIS PATIENTS AND CANNABIS ABUSE

We'll reach out to this number within 24 hrs